@article{9a7b0ad7eb2c44a1bcc39b50fd87d6b2,
title = "CAR T-cell therapy for pancreatic cancer",
abstract = "Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.",
keywords = "CAR T cells, adoptive cell therapy, checkpoint blockade, chimeric antigen receptor, immunotherapy",
author = "DeSelm, {Carl J.} and Tano, {Zachary E.} and Varghese, {Anna M.} and Adusumilli, {Prasad S.}",
note = "Funding Information: We thank Alex Torres of the Memorial Sloan Kettering Thoracic Surgery Service for his editorial assistance. The author's laboratory is supported by funding from Stand Up To Cancer—Cancer Research Institute Cancer Immunology Translational Cancer Research Grant (SU2C-AACR-DT1012). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. This research was also supported by the National Institutes of Health (P30 CA008748), U.S. Department of Defense (PR101053, LC110202, and BC132124), Memorial Sloan Kettering's Office of Technology Development, and the Mr. William H. Goodwin and Alice Goodwin, the Commonwealth Foundation for Cancer Research, and the Experimental Therapeutics Center. Publisher Copyright: {\textcopyright} 2017 Wiley Periodicals, Inc.",
year = "2017",
month = jul,
day = "1",
doi = "10.1002/jso.24627",
language = "English",
volume = "116",
pages = "63--74",
journal = "Journal of surgical oncology",
issn = "0022-4790",
number = "1",
}